Abstract #0093

ACRIN 6702 DWI Trial: The Value of Alternate ADC Metrics Compared to Standard ADC for Decreasing Breast MRI False-Positives

Habib Rahbar¹, Zheng Zhang², Justin Romanoff², Lucy G Hanna², Christopher E. Comstock³, and Savannah C Partridge¹

¹Radiology, University of Washington, Seattle, WA, United States, ²ACRIN Biostatistics Center, Brown University, Providence, RI, United States, ³Memorial Sloan Kettering Cancer Center, New York, NY, United States

The ACRIN 6702 trial confirmed that standard ADCs from multi b-value DWI acquisition are lower in malignancies than in benign lesions and that application of standard ADCs can eliminate one in five unnecessary biopsies. Secondary analysis from this trial demonstrated that application of alternate ADC metrics, including perfusion insensitive ADC_Ø and normalized ADC provide no practical benefit over standard ADC for improving conventional DCE-MRI performance. These findings suggest that standard ADC calculations alone are sufficient for improving breast MRI specificity and should be the primary metric included in the next edition of the BI-RADS atlas.

This abstract and the presentation materials are available to members only; a login is required.

Join Here